The Implantable insulin pump was first developed in the late 1970s by MiniMed and later aquired by Medtronic. Hundreds of people starting in the 1980s and many continue to do so today. Unlike the subcutaneous insulin pumps used today, implantable systems deliver insulin into the intraperitoneal cavity, the same area where a healthy pancreas releases insulin. This allows insulin to act 4-5x faster and clear the body sooner, more closely matching natural physiology.
Portal Diabetes is developing a next-generation implantable insulin pump that’s about 40–50% smaller than the original MiniMed, using a discreet, disc-shaped design that sits in the abdomen. The concept involves a small incision, placement of the pump under the skin, and a catheter delivering insulin directly into the intraperitoneal space, with refills done in-clinic every few months via an under-the-skin port.
If systems like this reach patients, faster insulin action could meaningfully change daily management by allowing dosing closer to meals, fewer prolonged lows, and less insulin lingering hours later. That speed also makes fully closed-loop automation more compelling, enabling smaller, faster adjustments and quicker insulin shutoff as glucose falls.
While a small number of legacy users remain in France, Portal’s implantable pump is still several years from commercialization. If it reaches the market, it could offer months-long insulin reservoirs, eliminate infusion sets and adhesives, minimize visible hardware, and fundamentally change the mental burden compared with today’s wearables.
We explore this technology in this week’s podcast episode with Stacy Chambliss, CEO of Portal Diabetes, and Lee Hartley, Chief Technology Officer, discussing how implantable pumps are being redesigned with smaller hardware, modern software, and the goal of a fully closed loop system. Listen to the episode above or watch below.
Want more?
For the latest diabetes tech, join our free newsletter.
If you like our content and want more, join Diabetech All Access—unlocking monthly Live Q&As, exclusive stories and industry analysis. Your support helps sustain our independent journalism and keeps this platform thriving.
Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a physician before making changes to your healthcare.